Results 201 to 210 of about 12,937,092 (315)

A teaching proposal for a short course on biomedical data science. [PDF]

PLoS Comput Biol
Chicco D, Coelho V.
europepmc   +1 more source

“Uneasy science”—the pooling of heterogeneous data: Reply of the authors (#2): [PDF]

, 2002
Carlos Alberto Petta, Melissa Hays
openalex   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Data science applied to the assessment of biological variation estimates. [PDF]

Adv Lab Med
Marques-Garcia F, Nieto-Librero A, Gonzalez-García N, Tejedor-Ganduxé X, Martinez-Bravo C.   +4 more
europepmc   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source

Leveraging data science to understand and address multimorbidity in sub-Saharan Africa: the MADIVA protocol. [PDF]

BMJ Health Care Inform
Glover K, Osler T, Adetunji K, Akumu T, Asiki G, Awuor D, Boua P, Bronstein V, Byamugisha J, Du Toit JD, Dwolatzky B, George J, Harris PA, Herbst K, Hofman K, Holden C, Iddi S, Kadengye DT, Kahn K, Kamp M, Khoza N, Kimongo F, Kisiangani I, Kogda DE, Klipin M, Levitt SP, Maghini D, Maila K, Maimela E, Nderitu DM, Makondo N, Maoyi ML, Mashaba RG, Masilela NG, Mathema T, Mpangase PT, Nyachowe DT, Ohene-Kwofie D, Robertson H, Speakman S, Thsehla E, Thwala SA, Zent R, Gómez-Olivé FX, Kabudula CW, Owili PO, Kyobutungi C, Ramsay M, Tollman S, Hazelhurst S.   +49 more
europepmc   +1 more source

Gridfields: Model-Driven Data Transformation in the Physical Sciences

, 2000
Bill Howe
openalex   +2 more sources

Data security is crucial for Japanese science [PDF]

, 2002
Eitaka Tsuboi, N. Kawahara, Tadahiro Mitsuishi, Akira Oshima, Shohei Yonemoto   +4 more
openalex   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Data Science with Julia

Journal of Statistical Software, 2020
James E. Helmreich
doaj   +1 more source